Jim Kramer here to share a short preview of my take on the market from today's members-only

CNBC Investing Club Morning Meeting.

Join the club for full access to the morning meeting every day at 1020 a.m.

Visit CnBC.com slash morning take to sign up today.

That's one word, morning take. First, let's get to Eli

Lilly, because after seeing Novo's numbers yesterday, Novo Nordus, I was pretty worried that they

wouldn't be able to balance this lower in price because of the agreement with the Trump

administration increase in volume dynamic. And they can. It was a great quarter, but guidance is what really stood out with revenue guiding the 80 to

83 billion. Consensus was 77 billion, 25% worth at the midpoint, EPS better than expected as well.

They are taking share, clearly.

Yeah, that's taking a couple share points this quarter.

Now, one of the things that I think I always look at are trials, and they're doing some trials.

They're finally doing the alcohol trials, I'm surprised that.

But they're also doing tobacco.

They're doing another form of arthritis because of knees when you're heavy

and I just want to point out that this thing is so far ahead in the trials in

Nova Nordus that there is going to be continued gulf because you knowvonoris isn't a

little just just just for new indications, expanding access.

We do have, or for Glipper on the pill, expected to be approved in April.

As we've learned from Nova Nortis, it is expanding the category.

It's not people right now as much switching from the injectables to the pill, the oral pill it is it's new people

coming into the category so that let's just talk about the pill for a second yes

...